Inomagen Therapeutics, Inc

Chicago, IL · Founded 2014 · Biotech · Private

Gene therapy for atrial fibrillation treatment

Claim this profile

Follows are private to you and power your alerts

Updated · rhythmtherapeutics.com

Sector
Biotech
Headquarters
Chicago, IL
Founded
2014
Latest Form D
$140K, Jun 2025
Total capital
$6.1M
Federal grants
$5.6M
3 awards · 2021–2023
Rank in peer group#93 of 514
Private capital raised
$540K
3 Form D · last Jun 2025
16 months since last filing
Federal contracts
None on recordNo federal contract awards found.
Granted patents
None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

201420162018202020222024FEDERAL ↑EQUITY ↓Cumulative $6.1M$463K$3.4M$1.7M1st Form D$200K2nd Form D$200K
201420162018202020222024FEDERAL ↑EQUITY ↓Cumulative $6.1M$463K$3.4M$1.7M1st Form D$200K2nd Form D$200K

Latest events

  • Private capital raisedForm D · SEC · 3rd filing$140K
  • Private capital raisedForm D · SEC · 2nd filing$200K
  • Federal grantHealth and Human S · Phase II · A New and Disruptive Gene Based Therapy for Atrial Fibrillation$1.7M
  • Federal grantHealth and Human S · Phase II · A New and Disruptive Gene Based Therapy for Atrial Fibrillation$3.4M
  • Federal grantHealth and Human S · Phase II · A New and Disruptive Gene Based Therapy for Atrial Fibrillation$463K
  • Private capital raisedForm D · SEC · 1st filing$200K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

  • Federal grants#93 · top 18%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings
  • James R. VoglerDirectorNamed in SEC Form D filings
  • Marc R. PennDirectorNamed in SEC Form D filings
  • Rishi AroraExecutive Officer, DirectorNamed in SEC Form D filings

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

  • VIVACELLE BIO INCSimilar federal contract value in Biotech · null in contracts
  • Nocion Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
  • FLAG THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts
  • ONCONAUT THERAPEUTICS INC.Similar federal contract value in Biotech · null in contracts
  • REGENE LLCSimilar federal contract value in Biotech · null in contracts
  • GAVIA BIO, LLCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through . SBIR and STTR awards through .